Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671286 | 0.78 | HDAC6 (0.34) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL27020189 | 0.78 | HDAC6 (0.34) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL29671232 | 0.76 | HDAC6 (0.33) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL29671262 | 0.76 | F2 (0.37) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL29671263 | 0.73 | SMN1; SMN2 (0.38) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL29671222 | 0.73 | HDAC6 (0.32) | HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL22909271 | 0.72 | CA1 (0.43) | HDAC3HDAC11HDAC8HDAC6ALDH1A1 | |
| SCHEMBL29671224 | 0.70 | HSD11B1 (0.41) | HDAC3HDAC11HDAC8HDAC6ALDH1A1 | |
| SCHEMBL22909406 | 0.69 | CA12 (0.31) | — | |
| SCHEMBL22909567 | 0.67 | CA1 (0.37) | HDAC3HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | HDAC3 478/4885HDAC11 1733/4885HDAC8 2150/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | HDAC3 2731/4885HDAC11 2800/4885HDAC8 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.